ampiopharma.com
Ampio Pharma reports positive results for both primary and secondary endpoints of pivotal Phase 3 trial of Ampion in severe osteoarthritis of the knee
- Ampion met its primary endpoint with 71% of Ampion treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee.
- Ampion is the first therapy indicated for signs and symptoms for severe osteoarthritis of the knee and will address a significant treatment gap.
No comments:
Post a Comment